


**PE/Dazzle™ 594 anti-mouse IFN-γ**


<b>Catalog # / Size:</b>	3129225 / 25 µg 3129230 / 100 µg
<b>Clone:</b>	XMG1.2
<b>Isotype:</b>	Rat IgG1, κ
<b>Immunogen:</b>	<i>E. coli</i> -expressed, recombinant mouse IFN-γ
<b>Reactivity:</b>	Mouse
<b>Preparation:</b>	The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Concentration:</b>	Lot-specific



PMA + Ionomycin-stimulated (6 hours) C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized, and then stained with IFN-γ (clone XMG1.2) PE/Dazzle™ 594 (top) or rat IgG1, κ PE/Dazzle™

**Applications:**

<b>Applications:</b>	Flow Cytometry
<b>Recommended Usage:</b>	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.



\* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

<b>Application Notes:</b>	<b>ELISA<sup>1-4,11,14</sup> or ELISPOT5</b> <b>Detection:</b> The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. <b>ELISA or ELISPOT Capture:</b> The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2
---------------------------	--

antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN- $\gamma$  (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).

**Flow Cytometry<sup>7,8,12,13,16</sup>:** The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN- $\gamma$ -producing cells within mixed cell populations.

**Neutralization<sup>1-3,9,10</sup>:** The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN- $\gamma$ . The LEAF™ purified antibody (Endotoxin <0.1 EU/ $\mu$ g, Azide-Free, 0.2  $\mu$ m filtered) is recommended for neutralization of mouse IFN- $\gamma$  bioactivity *in vivo* and *in vitro* (Cat. No. 505812). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

**Additional reported applications (for the relevant formats) include:**

Western blotting, immunohistochemical staining of frozen tissue sections<sup>6,22,23</sup>, and immunocytochemistry.

**Note:** For testing mouse IFN- $\gamma$  in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

**Application References:**

1. Abrams J, *et al.* 1992. *Immunol. Rev.* 127:5. (ELISA, Neut)
2. Sander B, *et al.* 1993. *J. Immunol. Meth.* 166:201. (ELISA, Neut)
3. Abrams J, *et al.* 1995. *Curr. Prot. Immunol.* John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, *et al.* 1993. *J. Immunoassay* 14:129. (ELISA)
5. Klinman D, *et al.* 1994. *Curr. Prot. Immunol.* John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, *et al.* 1991. *Immunol. Rev.* 119:65. (IHC)
7. Ferrick D, *et al.* 1995. *Nature* 373:255. (FC)
8. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
9. Peterson KE, *et al.* 2000. *J. Virol.* 74:5363. (Neut)
10. DeKrey GK, *et al.* 1998. *Infect. Immun.* 66:827. (Neut)
11. Dzhagalov I, *et al.* 2007. *J. Immunol.* 178:2113. (ELISA)
12. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366. (FC)
13. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181. (FC) [PubMed](#)
14. Xu G, *et al.* 2007. *J. Immunol.* 179:5358. (ELISA) [PubMed](#)
15. Montfort M, *et al.* 2004. *J. Immunol.* 173:4084. [PubMed](#)
16. Haring JS, *et al.* 2008. *J. Immunol.* 180:2855. (FC) [PubMed](#)
17. Jordan JM, *et al.* 2008. *Infect Immun.* 76:3717. [PubMed](#)
18. Tonkin DR, *et al.* 2008. *J. Immunol.* 181:4516. [PubMed](#)
19. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
20. Cui Y, *et al.* 2009. *Invest. Ophth. Vis. Sci.* 50:5811. (FC) [PubMed](#)
21. Mykkanen OT, *et al.* 2014. *PLoS One.* 9:114790. [PubMed](#)
22. Yokogawa M, *et al.* 2013. *Mol. Carcinog.* 52:760. (IHC)
23. Mottram PL, *et al.* 1998. *J Immunol.* 161:602. (IHC)

---

**Description:** IFN- $\gamma$  is a potent multifunctional cytokine which is secreted primarily by activated

NK cells and T cells. Originally characterized based on anti-viral activities, IFN- $\gamma$  also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN- $\gamma$  can upregulate MHC class I and II antigen expression by antigen-presenting cells.

**Antigen  
References:**

1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, *et al.* 1992. *Curr. Opin. Immunol.* 4:321.
3. Farrar M, *et al.* 1993. *Annu. Rev. Immunol.* 11:571